Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study to Investigate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of BR111 for Injection in Patients With Advanced Malignancies

Next Previous
Search
Trial Profile

A Phase I Study to Investigate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of BR111 for Injection in Patients With Advanced Malignancies

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 10 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BR 111 (Primary)
  • Indications B-cell lymphoma; Haematological malignancies; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors BioRay Pharmaceutical

Most Recent Events

  • 25 Apr 2025 Status changed from planning to not yet recruiting.
  • 20 Feb 2025 New trial record
  • 10 Feb 2025 According to a BioRay Pharmaceutical media release, the National Medical Products Administration (NMPA) has accepted the clinical trial application for BR111 for injection for the treatment of ROR1-positive hematological malignancies and solid tumors.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top